Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).
Carlos H. Barcenas, MD
Advertisement
Articles by Carlos H. Barcenas, MD
Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, discusses side effects of neratinib in patients with HER2-positive early-stage breast cancer.
Advertisement
Latest Updated Articles
Dr. Barcenas on Neratinib-Related Diarrhea in HER2+ Breast CancerFebruary 4th 2017
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
The OncFive: Top Oncology Articles for the Week of 5/31
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5